… multicentre study on the efficacy and tolerance of the TNF-α inhibitor infliximab in TA. …
infliximab, and these treatments had not been modified in the 3 months before initiating infliximab …

… To evaluate effectiveness and safety of infliximab dose escalation in Takayasu arteritis (TAK)
patients. To identify factors associated with refractoriness to standard-dose infliximab. …

… Infliximab originator is a monoclonal chimeric anti-TNF alpha … diseases such as Crohn’s
disease, 57 rheumatoid arthritis or … (26–41) have suggested that infliximab may help achieving …

… Objectives: Infliximab (IFX) is widely used in patients with refractory Takayasu arteritis (TAK).
Recently, the IFX-biosimilar CT-P13 has been introduced for the treatment of inflammatory …

… with anti-TNF-α therapy 2,7 . We describe 3 cases with apparent disease control for several
… Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. …

… infliximab in refractory patient with Takayasu arteritis (TA) is assumed to be favorable, based
on retrospective studies with limited sample size [1, 2] in which infliximab … use of infliximab …

… Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the … Briefly, anti TNF-α agents
appear to be effective in treating TAK … in GCA and anti-TNF-α agents (mainly infliximab) in TAK. …

… from the literature) with refractory Takayasu arteritis treated with anti TNF-α. The mean age
… regimens before anti TNF-α therapy. First line of anti-TNF-α included infliximab (IFX) in 81% …

… infliximab at that time (2009), we chose this TNFα inhibitor. The first case series on TNFα
inhibitor treatment of Takayasu arteritis … tolerance of infliximab in refractory Takayasu arteritis: …

… is to analyze the efficacy and tolerance of tocilizumab in patients with Takayasu arteritis (TA). …
Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicenter study …